Skip to main content

Table 2 Results

From: Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction – a prospective cohort pilot study within a randomized clinical trial

 

Chemotherapy

 

Chemoradiotherapy

  

Variable

Pre neoadjuvant

Post neoadjuvant

P a

Pre neoadjuvant

Post neoadjuvant

p a

p b

EF (%)

59 (56–62)

57 (53–60)

>0.99

60 (57–64)

59 (55–63)

>0.99

0.80

GS (%)

−17.6 (−16, −19)

−15.7 (−14, −17)

0.26

−17.3 (−16, −19)

−16.1 (−14, −18)

>0.99

0.59

MAPSE sept (cm/s)

12.5 (11.5–13.5)

12.1 (11.2–13.1)

>0.99

12.6 (11.4–13.8)

11.1 (10.1–12.2)

0.02

0.09

MAPSE lat (cm/s)

11.5 (10.4–12.6)

11.2 (10.2–12.3)

>0.99

11.2 (10.0–12.4)

11.0 (9.8–12.1)

>0.99

0.96

E (cm/s)

72.0 (62.6–81.4)

68.1 (62.2–74.1)

>0.99

78.8 (68.4–89.3)

64.1 (57.2–70.9)

0.01

0.09

A (cm/s)

67.8 (58.2–77.5)

74.6 (63.9–85.3)

0.37

82.0 (71.1–92.7)

83.7 (71.6–95.9)

0.98

0.41

E/A

1.08 (0.93–1.25)

0.95 (0.81–1.10)

0.43

0.97 (0.82–1.14)

0.77 (0.65–0.92)

0.03

0.39

NT–ProBNP (ηg/l)

93 (58–149)

108 (70–167)

>0.99

65 (32–130)

154 (92–260)

0.05

0.07

Exercise test (W)

150 (135–165)

133 (115–151)

0.03

151 (133–151)

118 (96–140)

0.001

0.10

  1. Data are presented as mean (95% confidence interval). aMixed models test of within-group changes; bMixed models test of interaction effect; EF, ejection fraction; GS, global strain; MAPSE, mitral annular plane systolic excursion; NT-proBNP, N-terminal pro-brain natriuretic peptide.